Active Ingredient History
Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.Vincristine was marketed under the brand name Oncovin, but was discontinued. In 2012 the FDA approved a Liposomal formulation of Vincristine, named MARQIBO KIT. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Leukemia, Lymphoid (approved 2012)
Acne Vulgaris (Phase 2)
Adenocarcinoma (Phase 1)
Adrenocortical Carcinoma (Phase 2)
Allergy and Immunology (Phase 1)
Angiomatosis (Phase 2)
Antigens, CD (Phase 1/Phase 2)
Astrocytoma (Phase 3)
Basal Cell Nevus Syndrome (Phase 2)
Beckwith-Wiedemann Syndrome (Phase 3)
Blast Crisis (Phase 2)
Bone Marrow Cells (Phase 1/Phase 2)
Bone Marrow Diseases (Phase 1)
Bone Neoplasms (Phase 2)
Brain Diseases (Phase 1)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 4)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Cardiotoxicity (Phase 3)
Castleman Disease (Phase 1)
Central Nervous System Neoplasms (Phase 3)
Child (Phase 2)
Choroid Plexus Neoplasms (Phase 3)
Cognition Disorders (Phase 2)
Colorectal Neoplasms (Phase 3)
Desmoplastic Small Round Cell Tumor (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 1/Phase 2)
Down Syndrome (Phase 3)
Drugs, Investigational (Phase 2)
Drug Therapy (Phase 2)
Endoscopy (Phase 2)
Enteropathy-Associated T-Cell Lymphoma (Phase 4)
Ependymoma (Phase 3)
Eye Diseases, Hereditary (Phase 1)
Fusion Proteins, bcr-abl (Phase 2)
Ganglioneuroblastoma (Phase 2)
Gastrointestinal Neoplasms (Phase 1)
Geriatrics (Phase 3)
Gestational Trophoblastic Disease (Phase 3)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 3)
Gliosarcoma (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 3)
Hemangioma (Phase 2)
Hematologic Diseases (Phase 1)
Hematopoietic Stem Cell Transplantation (Phase 1/Phase 2)
Hepatoblastoma (Phase 3)
Herpesvirus 8, Human (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 3)
HIV (Phase 2)
HIV Infections (Phase 4)
Hodgkin Disease (Phase 3)
HTLV-I Infections (Phase 1)
Hypertrophy (Phase 3)
Immunoglobulins (Phase 3)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 1/Phase 2)
Kasabach-Merritt Syndrome (Phase 2)
Kidney Diseases (Phase 3)
Kidney Neoplasms (Phase 3)
Lenalidomide (Phase 2)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)
Leukemia, Lymphoid (Phase 4)
Leukemia-Lymphoma, Adult T-Cell (Phase 4)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 1/Phase 2)
Leukemia, T-Cell (Phase 2/Phase 3)
Liver Neoplasms (Phase 3)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 3)
Lymphoma, AIDS-Related (Phase 2)
Lymphoma, B-Cell (Phase 4)
Lymphoma, B-Cell, Marginal Zone (Phase 3)
Lymphoma, Extranodal NK-T-Cell (Phase 3)
Lymphoma, Follicular (Phase 4)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Lymphoma, Large-Cell, Anaplastic (Phase 4)
Lymphoma, Large-Cell, Immunoblastic (Phase 4)
Lymphoma, Mantle-Cell (Phase 4)
Lymphoma, Non-Hodgkin (Phase 4)
Lymphoma, Primary Effusion (Phase 1/Phase 2)
Lymphoma, T-Cell (Phase 4)
Lymphoma, T-Cell, Peripheral (Phase 4)
Lymphomatoid Granulomatosis (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Mediastinal Neoplasms (Phase 4)
Medulloblastoma (Phase 4)
Melanoma (Phase 2)
Mesothelioma, Malignant (Phase 3)
Mucositis (Phase 3)
Multiple Myeloma (Phase 3)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloma Proteins (Phase 3)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 4)
Neuroblastoma (Phase 3)
Neuroectodermal Tumors (Phase 3)
Neuroectodermal Tumors, Primitive (Phase 1)
Neuroendocrine Tumors (Phase 1)
Neurofibromatosis 1 (Phase 3)
Neutropenia (Phase 2)
N-Myc Proto-Oncogene Protein (Phase 1/Phase 2)
Oligodendroglioma (Phase 3)
Oncogenes (Phase 2)
Optic Nerve Glioma (Phase 1/Phase 2)
Osteosarcoma (Phase 2)
Ototoxicity (Phase 3)
Ovarian Neoplasms (Phase 2)
Peritoneal Neoplasms (Phase 1)
Philadelphia Chromosome (Phase 2)
Plasmablastic Lymphoma (Phase 2)
Plasmacytoma (Phase 2)
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Prognosis (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 4)
Retinal Neoplasms (Phase 3)
Retinoblastoma (Phase 4)
Retroperitoneal Neoplasms (Phase 1)
Rhabdoid Tumor (Phase 3)
Rhabdomyosarcoma (Phase 3)
Rhabdomyosarcoma, Alveolar (Phase 3)
Rhabdomyosarcoma, Embryonal (Phase 3)
Risk Factors (Phase 2)
Sarcoma (Phase 3)
Sarcoma, Ewing (Phase 3)
Sarcoma, Kaposi (Phase 3)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 3)
Stomatitis (Phase 2)
Teratoma (Phase 2)
Testicular Neoplasms (Phase 3)
Thalidomide (Phase 3)
Thrombocytopenia (Phase 2)
Translocation, Genetic (Phase 2)
Treatment Refusal (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Waldenstrom Macroglobulinemia (Phase 2)
Wilms Tumor (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
